...
首页> 外文期刊>Oncology >The Future of NSCLC: Molecular Profiles Guiding Treatment Decisions
【24h】

The Future of NSCLC: Molecular Profiles Guiding Treatment Decisions

机译:NSCLC的未来:指导治疗决策的分子谱

获取原文
获取原文并翻译 | 示例
           

摘要

The authors of "ALK-Targeted Therapy for Lung Cancer: Ready for Prime Time," in this issue of ONCOLOGY, address the newest developments in the field of targeted therapies for advanced non-small-cell lung cancer (NSCLC): the detection of the anaplastic lymphoma kinase (ALK) gene translocation and the evaluation of crizotinib, a dual inhibitor of the MET tyrosine kinase and ALK, as therapy for patients with lung tumors harboring the ALK translocation. The last decade has been one of the most exciting periods in thoracic oncology research. During this time, targeted therapies have reached FDA approval and the median overall survival for patients with metastatic NSCLC has reached an all-time high of more than 1 year. Certain subpopulations of NSCLC patients have even greater survival times-namely in the never-smoking and minimal former-smoking populations. Previously, clinical and histologic parameters were the sole determinants of which agents to administer. However, increasing use of molecular tools applied to human tumors has altered the paradigm and will likely drive treatment decisions in the future. The uncontested benefit of EGFR tyrosine kinase inhibitors for patients with EGFR activating mutations[1] has clearly demonstrated the feasibility and power of tumor molecular profiling as a guide for clinical treatment decisions and has paved the way for a new era of personalized treatment for NSCLC.
机译:在本期《肿瘤学》上,“针对肺癌的ALK靶向治疗:准备黄金时间”探讨了晚期非小细胞肺癌(NSCLC)靶向治疗领域的最新进展:变性淋巴瘤激酶(ALK)基因易位,并评估crizotinib(MET酪氨酸激酶和ALK的双重抑制剂)作为具有ALK易位的肺肿瘤患者的治疗方法。过去十年是胸部肿瘤学研究中最激动人心的时期之一。在此期间,靶向疗法已获得FDA批准,转移性NSCLC患者的平均总生存期已达到1年多的历史最高水平。非小细胞肺癌患者的某些亚群具有更长的生存时间,即在从不吸烟和极少吸烟的人群中。以前,临床和组织学参数是决定使用哪种药物的唯一决定因素。然而,越来越多地使用应用于人类肿瘤的分子工具已经改变了这一范例,并可能在未来推动治疗决策。 EGFR酪氨酸激酶抑制剂对具有EGFR激活突变的患者的无可争议的益处[1]清楚地证明了肿瘤分子谱分析作为临床治疗决策指南的可行性和力量,并为NSCLC个性化治疗的新时代铺平了道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号